| 20 0.03 (0.15%) | 04-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Cardiovascular Systems, Inc. (CSI) is a medical technology firm dedicated to the creation and commercialization of advanced therapeutic solutions for individuals suffering from peripheral and coronary artery diseases, serving markets both within the United States and internationally. For peripheral artery disease (PAD), CSI offers a range of catheter-based systems designed to treat various types of arterial plaque, including severely calcified deposits, in arteries located both above and below the knee. These systems aim to provide improved outcomes compared to conventional surgical, interventional, and pharmacological treatments. The company also provides supplementary peripheral support products. Regarding coronary artery disease (CAD), CSI supplies the Diamondback 360 Coronary Orbital Atherectomy System (OAS). This specialized device is engineered to aid in the successful placement of stents in CAD patients who present with heavily calcified coronary artery lesions and are deemed suitable candidates for percutaneous transluminal coronary angioplasty or stenting procedures. Furthermore, CSI manufactures and distributes essential procedural accessories such as guidewires, catheters, balloons, and embolic protection systems, along with other supporting products for its OAS technology. In a collaborative effort, Cardiovascular Systems, Inc. has partnered with Chansu Vascular Technologies, LLC, focusing on the development of innovative everolimus drug-coated balloons for both peripheral and coronary applications. Originally established in 1989 as Shturman Cardiology Systems, Inc., the company officially adopted its current name, Cardiovascular Systems, Inc., in January 2003. Its corporate headquarters are located in Saint Paul, Minnesota.
Fri, 28 Apr 2023
Abbott completes $850M acquisition of Minnesota-based Cardiovascular Systems - cardiovascularbusiness.com
Thu, 27 Apr 2023
Abbott completes $890M acquisition of Cardiovascular Systems - MassDevice
Wed, 26 Apr 2023
Expanding vascular offerings to improve patient care - Abbott
Wed, 15 Feb 2023
Abbott to Acquire Cardiovascular Systems, Inc. - dicardiology.com
Fri, 10 Feb 2023
Abbott to Acquire Cardiovascular Systems, Inc. - Healthcare Packaging
Thu, 09 Feb 2023
Abbott to buy Cardiovascular Systems, Inc. for $890M - Medical Marketing and Media
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|